ZyVersa Therapeutics (ZVSA) Competitors $1.91 -0.10 (-4.98%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends ZVSA vs. COEP, PULM, VIRX, CANF, APM, GLTO, ONVO, EGRX, MBRX, and TFFPShould you be buying ZyVersa Therapeutics stock or one of its competitors? The main competitors of ZyVersa Therapeutics include Coeptis Therapeutics (COEP), Pulmatrix (PULM), Viracta Therapeutics (VIRX), Can-Fite BioPharma (CANF), Aptorum Group (APM), Galecto (GLTO), Organovo (ONVO), Eagle Pharmaceuticals (EGRX), Moleculin Biotech (MBRX), and TFF Pharmaceuticals (TFFP). These companies are all part of the "pharmaceutical products" industry. ZyVersa Therapeutics vs. Coeptis Therapeutics Pulmatrix Viracta Therapeutics Can-Fite BioPharma Aptorum Group Galecto Organovo Eagle Pharmaceuticals Moleculin Biotech TFF Pharmaceuticals ZyVersa Therapeutics (NASDAQ:ZVSA) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations. Which has more volatility and risk, ZVSA or COEP? ZyVersa Therapeutics has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.91, suggesting that its share price is 191% less volatile than the S&P 500. Does the MarketBeat Community prefer ZVSA or COEP? Coeptis Therapeutics received 2 more outperform votes than ZyVersa Therapeutics when rated by MarketBeat users. However, 100.00% of users gave ZyVersa Therapeutics an outperform vote while only 83.33% of users gave Coeptis Therapeutics an outperform vote. CompanyUnderperformOutperformZyVersa TherapeuticsOutperform Votes3100.00% Underperform VotesNo VotesCoeptis TherapeuticsOutperform Votes583.33% Underperform Votes116.67% Is ZVSA or COEP more profitable? ZyVersa Therapeutics' return on equity of -172.50% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ZyVersa TherapeuticsN/A -172.50% -90.88% Coeptis Therapeutics N/A -5,710.19%-413.75% Do analysts rate ZVSA or COEP? ZyVersa Therapeutics presently has a consensus target price of $120.00, suggesting a potential upside of 6,182.72%. Given ZyVersa Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe ZyVersa Therapeutics is more favorable than Coeptis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Coeptis Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to ZVSA or COEP? In the previous week, ZyVersa Therapeutics had 4 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 4 mentions for ZyVersa Therapeutics and 0 mentions for Coeptis Therapeutics. ZyVersa Therapeutics' average media sentiment score of 0.40 beat Coeptis Therapeutics' score of -1.00 indicating that ZyVersa Therapeutics is being referred to more favorably in the media. Company Overall Sentiment ZyVersa Therapeutics Neutral Coeptis Therapeutics Negative Which has stronger valuation and earnings, ZVSA or COEP? Coeptis Therapeutics has higher revenue and earnings than ZyVersa Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZyVersa TherapeuticsN/AN/A-$98.30MN/AN/ACoeptis Therapeutics$80K98.31-$21.27M-$0.47-0.42 Do insiders & institutionals have more ownership in ZVSA or COEP? 3.9% of ZyVersa Therapeutics shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 0.6% of ZyVersa Therapeutics shares are owned by company insiders. Comparatively, 21.5% of Coeptis Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryZyVersa Therapeutics beats Coeptis Therapeutics on 9 of the 14 factors compared between the two stocks. Ad Chaikin AnalyticsSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). Get ZyVersa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZVSA vs. The Competition Export to ExcelMetricZyVersa TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.97M$7.02B$5.39B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E RatioN/A9.47113.8115.12Price / SalesN/A381.571,483.2593.03Price / CashN/A47.3339.6434.05Price / Book0.025.324.665.02Net Income-$98.30M$153.56M$119.06M$225.46M7 Day Performance-9.05%0.12%0.79%0.37%1 Month Performance-16.23%15.23%5.65%3.57%1 Year Performance-94.36%41.16%36.76%29.42% ZyVersa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZVSAZyVersa Therapeutics2.947 of 5 stars$1.91-5.0%$120.00+6,182.7%-93.9%$1.97MN/A0.002COEPCoeptis Therapeutics0.4878 of 5 stars$0.20flatN/A-83.6%$7.87M$80,000.00-0.422Short Interest ↑Gap DownPULMPulmatrix0.3224 of 5 stars$2.13-3.2%N/A+12.7%$7.77M$7.30M-0.7220Analyst ForecastVIRXViracta Therapeutics3.2559 of 5 stars$0.19-4.9%$5.50+2,729.2%-70.1%$7.66MN/A-0.1720Gap DownCANFCan-Fite BioPharma1.4184 of 5 stars$2.16+0.5%$18.00+733.3%-4.2%$7.65M$740,000.00-1.218Analyst DowngradeGap UpAPMAptorum Group1.4262 of 5 stars$1.45+1.4%N/A-13.0%$7.53M$430,000.000.0030GLTOGalecto3.2997 of 5 stars$6.75-1.5%$10.00+48.1%-47.5%$7.36MN/A-0.2940Earnings ReportNews CoverageONVOOrganovo0.2259 of 5 stars$0.47+2.2%N/A-62.8%$7.15M$73,000.00-0.3420EGRXEagle Pharmaceuticals2.1043 of 5 stars$0.55-8.3%N/A-96.1%$7.14M$257.55M0.00134News CoverageMBRXMoleculin Biotech1.9336 of 5 stars$2.45-5.8%$35.00+1,328.6%-66.1%$6.97MN/A0.0020TFFPTFF Pharmaceuticals1.9697 of 5 stars$1.97-21.2%$44.00+2,133.5%-72.1%$6.84M$730,000.00-0.2519 Related Companies and Tools Related Companies COEP Alternatives PULM Alternatives VIRX Alternatives CANF Alternatives APM Alternatives GLTO Alternatives ONVO Alternatives EGRX Alternatives MBRX Alternatives TFFP Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ZVSA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZyVersa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZyVersa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
